iShares US Pharmaceuticals ETF

IHE

Market cap $578M

Overview Fund Activity

70.90 USD

-0.84

1.17%

At close Updated Sep 12, 4:00 PM EDT

1 day

-1.17%

5 days

-0.55%

1 month

5.81%

3 months

4.46%

6 months

2%

Year to date

8.05%

1 year

-0.53%

5 years

28.47%

10 years

28.37%

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

2.92% more ownership

Funds ownership: 55.86% [Q1] → 58.78% (+2.92%) [Q2]

5% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 39

6% less capital invested

Capital invested by funds: $345M [Q1] → $326M (-$19.2M) [Q2]

7% less funds holding

Funds holding: 149 [Q1] → 139 (-10) [Q2]

42% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 24

See Fund Rankings

Financial journalist opinion

Zacks Investment Research

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the iShares U.S. Pharmaceuticals ETF (IHE), a passively managed exchange traded fund launched on May 1, 2006.

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

Zacks Investment Research

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

The iShares U.S. Pharmaceuticals ETF (IHE) was launched on 05/01/2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Pharma segment of the equity market.

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

IHE: Healthcare Dashboard For June

The healthcare providers industry is undervalued by about 22% versus 11-year averages, while pharma/biotech and life science tools trade near historical baseline in valuation. IHE ETF offers exposure to U.S. pharmaceuticals, with 47% of assets in Eli Lilly and Johnson & Johnson, posing significant concentration risk. IHE has lagged XLV in long-term returns but outperformed over the past 12 months, offering sufficient liquidity for both investors and traders.

IHE: Healthcare Dashboard For June

Healthcare Sector Checkup As U.S. Looks To Change Regulations

Outlook for pharma sector as Trump pushes for regulatory changes. The impact of tariffs on drugmakers.

Healthcare Sector Checkup As U.S. Looks To Change Regulations

Zacks Investment Research

ETFs on the Move Post U.S.-China Trade Deal

Let's delve into the ETF world following the 90-day U.S.-China trade deal.

ETFs on the Move Post U.S.-China Trade Deal

Zacks Investment Research

Pharma ETFs in Focus on Trump's Drug Price Overhaul

Trump's plan to slash the price of prescription drugs by 30% put pharma ETFs in focus.

Pharma ETFs in Focus on Trump's Drug Price Overhaul

Zacks Investment Research

A Look at Pharma ETFs After Strong Q1 Earnings

Many pharma bigwigs reported solid results, with some beating on earnings or revenues or both.

A Look at Pharma ETFs After Strong Q1 Earnings

Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks

As the drug industry is in the middle of a growing policy maelstrom in Washington, D.C., investors are closely watching pharmaceutical ETFs to measure market sentiment and ride out the emerging volatility.

Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks

Zacks Investment Research

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

Launched on 05/01/2006, the iShares U.S. Pharmaceuticals ETF (IHE) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Pharma segment of the equity market.

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

Trump teases targeted tariffs on overseas drug manufacturers

With the next set of White House–imposed tariffs just hours away from taking effect — including the attention-hogging 104% rate to be levied on products from China as they're imported into the U.S. — President Donald Trump indicated he intends to roll out more product-specific tariffs down the road.

Trump teases targeted tariffs on overseas drug manufacturers

See News Rankings

Charts implemented using Lightweight Charts™